Pharma's Next Big Deal
This carefully curated group of stocks features promising biotech companies with valuable drug pipelines. These smaller firms could become the next targets for lucrative partnerships or acquisitions by pharmaceutical giants, similar to Glenmark's recent $2 billion deal with AbbVie.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
Bridgebio Pharma Inc
BBIO
Current price
$51.32
Its focus on developing transformative medicines for genetic diseases makes it a prime acquisition target for larger firms seeking entry into the rare...
Its focus on developing transformative medicines for genetic diseases makes it a prime acquisition target for larger firms seeking entry into the rare disease market.
Royalty Pharma plc
RPRX
Current price
$36.35
As a buyer of biopharmaceutical royalties, Royalty Pharma directly benefits from the trend of smaller companies out-licensing successful drugs to larg...
As a buyer of biopharmaceutical royalties, Royalty Pharma directly benefits from the trend of smaller companies out-licensing successful drugs to larger ones.
ORIC Pharmaceuticals
ORIC
Current price
$9.71
The company's specific focus on overcoming cancer resistance addresses a critical unmet need, making its pipeline highly valuable for a potential phar...
The company's specific focus on overcoming cancer resistance addresses a critical unmet need, making its pipeline highly valuable for a potential pharma partner.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
Big pharma companies increasingly acquire innovation by partnering with smaller, specialized biotech firms. This creates opportunities to invest in potential acquisition targets before they receive partnership offers that can send stock prices soaring, as seen with Glenmark's nearly $2 billion AbbVie deal.
What You Need to Know
These companies are clinical-stage biopharma firms developing novel therapies in high-demand areas like oncology and rare genetic diseases. They absorb early R&D risk but offer significant upside potential if their innovative pipelines attract partnership interest from larger pharmaceutical companies.
Why These Stocks
Each company in this group has been selected for its innovative pipeline and similarity to the profile of firms that typically attract major partnership deals. They represent smaller biotech companies with valuable drug candidates that could be attractive acquisition targets for pharmaceutical giants.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+371.43%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 371.43% over the next year.
Stocks Rated Buy by Analysts
14 of 14 assets in this group are rated Buy by professional analysts.
Why You'll Want to Watch These Stocks
Billion-Dollar Deal Potential
These companies could be the next Glenmark, which secured a $2 billion licensing deal with AbbVie. Even early-stage partnerships can bring substantial upfront payments, sometimes in the hundreds of millions.
Innovation That Big Pharma Needs
Large pharmaceutical companies increasingly depend on smaller biotech firms for innovation. With patents expiring and pressure to deliver new drugs, these nimble companies with cutting-edge pipelines become valuable acquisition targets.
Takeover Premium Opportunity
When acquisition offers are announced, target company stocks typically surge. By investing before a deal is announced, you position yourself to potentially benefit from the significant premiums paid in biopharma acquisitions.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Uncle Sam's Semiconductor Stake
The U.S. government is considering an equity stake in Intel to boost domestic semiconductor manufacturing. This strategic move could create a ripple effect, benefiting other American companies involved in the chip-making industry.
The Cybersecurity Consolidation Wave
Accenture's record-breaking acquisition of CyberCX signals a major consolidation trend in the cybersecurity sector. This move highlights the growing demand for AI-powered security solutions, creating potential opportunities for other specialized cybersecurity firms to benefit from increased investment and M&A activity.
American Chipmakers: A Tariff-Driven Shift
President Trump has threatened to impose tariffs of up to 300% on semiconductors to boost domestic production. This creates a potential investment opportunity in U.S.-based semiconductor companies that stand to gain from a shift toward onshore manufacturing.
Frequently Asked Questions
Everything you need to know about the product and billing.